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LETTERS TO THE EDITOR
Beta-Blockers and Ventricular
Arrhythmias in Dilated Cardiomyopathy
We read with interest the article by Di Lenarda et al. (1) in a recent
issue of the Journal. The authors conclude that in patients with
dilated cardiomyopathy who are poor responders to metoprolol,
carvedilol treatment was associated with a favorable effect on left
ventricular function as well as on ventricular arrhythmias. We
would like to add some specific comments about ventricular
arrhythmias. We are somewhat surprised about the baseline
characteristics of the two groups of patients who thereafter
received metoprolol or carvedilol. It seems clear that patients in the
carvedilol group had a higher prevalence of nonsustained ventric-
ular tachycardia (mean value 10 times higher than that in the
metoprolol group) and of ventricular couplets (mean value and
SEM .20 times higher than that in the metoprolol group),
although a statistical difference was not found between the two
groups (Table 1). The statistical method used seems rather
sophisticated, but no precise information is given on what variables
were used for adjustment in the comparison of prevalence of
ventricular arrhythmias, and the adjusted means are not shown. In
view of the small number of patients in each group, it is not certain
whether a simple nonparametric test would have been more
appropriate. Although the inhomogeneity in the baseline charac-
teristics does not seem to exist for ventricular ectopic beats, it is
generally accepted that the prognostic value of ventricular arrhyth-
mias is more important for ventricular couplets or nonsustained
ventricular tachycardia than for isolated beats. This point has some
importance to evaluate the compared effects of metoprolol and
carvedilol on ventricular arrhythmias, because it may have been
easier to find a favorable effect in the carvedilol group if its baseline
characteristics were more severe; similarly a beneficial effect may
not have been demonstrated in the metoprolol group because the
better baseline characteristics in this group may hardly improve
with medical treatment. It is important to separate the effects due
to treatment from the effect of regression toward the mean (2). A
phenomenon of regression toward the mean in both groups seems
possible, because at 12 months, the mean of ventricular couplets
remained higher in the carvedilol group (1.9/h) than in the
metoprolol group (1.7/h), and the mean of nonsustained ventric-
ular tachycardia also remained higher in the carvedilol group
(0.08/h) than in the metoprolol group (0.04/h). There are actually
no clear data on the specific effect of carvedilol on sudden death
in large studies of patients with congestive heart failure, and the
precise level of significance for the reduction of the relative risk
of sudden death was not given in the U.S. Carvedilol Study (3).
In contrast, the reduction of sudden death with metoprolol in
the MERIT-HF study (4) was highly significant (relative risk
0.59, p 5 0.0002). We recognize that the attempt of Di
Lenarda to evaluate two different beta-blockers in a selected
group of patients with persistent left ventricular dysfunction is
of interest, but we consider that the conclusion of a benefit of
carvedilol on ventricular arrhythmias remains speculative.
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REPLY
We are grateful for the opportunity to respond to the comments by
Drs. Fauchier and Giraudeau concerning our recent article in the
Journal (1). Specifically, they draw attention to the differences in
the baseline arrhythmic profile of our patients with dilated cardio-
myopathy who thereafter received carvedilol or metoprolol. We
agree that the inhomogeneity in patient characteristics is surely an
important issue, and, although in general terms, in our article, we
have already commented on this point by admitting the existence
of some differences in baseline characteristics between the carve-
dilol and metoprolol groups. With reference to the specific
objection made by Drs. Fauchier and Giraudeau, we recognize that
patients receiving carvedilol had a higher prevalence of both
nonsustained ventricular tachycardia (NSVT) and ventricular cou-
plets (VC), although these differences did not reach statistical
significance (in all likelihood because of the small number of
patients and the high variability).
Because a more severe arrhythmic picture at baseline might have
contributed to the finding of a favorable effect of carvedilol on
NSVT and VC, Drs. Fauchier and Giraudeau are correct when
they claim more precise information on the variables used for
adjustment in the comparison of the prevalence of ventricular
arrhythmias. In short, we can specify that all differences were
tested considering the baseline arrhythmic profile and concurrent
amiodarone therapy as potentially confounding factors (Table 1).
On the basis of this statistical approach, we believe that the
potential impact of patient heterogeneity on our results has been
limited, and, moreover, that the effects seen on ventricular arrhyth-
mias are more likely due to beta-blocker therapy than to a
phenomenon of regression toward the mean. A simple test (both
parametric or nonparametric) would hardly be appropriate in
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